Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
1.
Curr Oncol ; 22(2): e100-12, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25908915

RESUMO

To meet the needs of patients, Canadian surgical and medical oncology leaders in the treatment of peritoneal surface malignancies (psms), together with patient representatives, formed the Canadian HIPEC Collaborative Group (chicg). The group is dedicated to standardizing and improving the treatment of psm in Canada so that access to treatment and, ultimately, the prognosis of Canadian patients with psm are improved. Patients with resectable psm arising from colorectal or appendiceal neoplasms should be reviewed by a multidisciplinary team including surgeons and medical oncologists with experience in treating patients with psm. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should be offered to appropriately selected patients and performed at experienced centres. The aim of this publication is to present guidelines that we recommend be applied across the country for the treatment of psm.

2.
Curr Oncol ; 27(6): e621-e631, 2020 12.
Artigo em Inglês | MEDLINE | ID: mdl-33380878

RESUMO

Modern management of colorectal cancer (crc) with peritoneal metastasis (pm) is based on a combination of cytoreductive surgery (crs), systemic chemotherapy, and hyperthermic intraperitoneal chemotherapy (hipec). Although the role of hipec has recently been questioned with respect to results from the prodige 7 trial, the role and benefit of a complete crs were confirmed, as observed with a 41-month gain in median survival in that study, and 15% of patients remaining disease-free at 5 years. Still, crc with pm is associated with a poor prognosis, and good patient selection is essential. Many questions about the optimal management approach for such patients remain, but all patients with pm from crc should be referred to, or discussed with, a pm surgical oncologist, because cure is possible. The objective of the present guideline is to offer a practical approach to the management of pm from crc and to reflect on the new practice standards set by recent publications on the topic.


Assuntos
Neoplasias Colorretais , Hipertermia Induzida , Neoplasias Peritoneais , Canadá , Neoplasias Colorretais/terapia , Procedimentos Cirúrgicos de Citorredução , Humanos , Neoplasias Peritoneais/terapia
3.
Curr Oncol ; 25(3): e200-e208, 2018 06.
Artigo em Inglês | MEDLINE | ID: mdl-29962846

RESUMO

Background: Some surgeons change gloves and instruments after the extirpative phase of cancer surgery with the intent of reducing the risk of local and wound recurrence. Although this practice is conceptually appealing, the evidence that gloves or instruments act as vectors of cancer-cell seeding in the clinical setting is weak. To determine the potential effect of further investigation of this question, we surveyed the practices and beliefs of a broad spectrum of surgeons who operate on cancer patients. Methods: Using a modified Dillman approach, a survey was mailed to all 945 general surgeons listed in the College of Physicians and Surgeons of Ontario public registry. The survey consisted of multiple-choice and free-text response questions. Responses were tabulated and grouped into themes, including specific intraoperative events and surgeon training. Predictive variables were analyzed by chi-square test. Results: Of 459 surveys returned (adjusted response rate: 46%), 351 met the inclusion criteria for retention. Of those respondents, 52% reported that they change gloves during cancer resections with the intent of decreasing the risk of tumour seeding, and 40%, that they change instruments for that purpose. The proportion of respondents indicating that they take measures to protect the wound was 73% for laparoscopic cancer resections and 31% for open resections. Training and years in practice predicted some of the foregoing behaviours. The most commonly cited basis for adopting specific strategies to prevent tumour seeding was "gut feeling," followed by clinical training. Most respondents believe that it is possible or probable that surgical gloves or instruments harbour malignant cells, but that a cancer recurrence proceeding from that situation is unlikely. Conclusions: There is no consensus on how gloves and instruments should be handled in cancer operations. Further investigation is warranted.


Assuntos
Luvas Protetoras/normas , Luvas Cirúrgicas/normas , Inoculação de Neoplasia , Humanos , Recidiva Local de Neoplasia , Cirurgiões , Inquéritos e Questionários
4.
Eur J Surg Oncol ; 43(2): 423-431, 2017 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-27890349

RESUMO

INTRODUCTION: Desmoplastic small round cell tumor (DSRCT) is a rare mesenchymal malignancy. We describe our experience with treating DSRCT at a large sarcoma referral center. METHODS: A retrospective chart review was performed on DSRCT patients referred to our institution (1998-2014). Pathology specimens were reviewed to confirm the diagnosis. Clinical and imaging were extracted and summarized with descriptive statistics. Univariate analysis was performed to evaluate the association between patient, tumor, and treatment variables and overall survival (OS). RESULTS: In this study cohort of 20 patients, median age at presentation was 29 y (range 18-43) and 90% were male. Fifty-five percent presented with metastasis. Patients underwent chemotherapy (n = 20), radiation therapy (n = 3), and cytoreductive surgery (CRS) (n = 5). Median OS was 22 m (interquartile range: 12-28 m). Five-year OS rate was 20%. Extra-abdominal metastasis was associated with a higher hazard ratio (HR) of mortality (HR: 3.1, 95% C.I. 1.0-9.4, p = 0.04), while CRS improved OS (HR: 0.1, 95% C.I. 0.03-0.7, p = 0.02). CONCLUSIONS: Despite aggressive treatment, less than half of the patients were dead of DSRCT within 2 years of presentation. Although a select group of patients who underwent CRS had improved OS, novel treatments are urgently needed.


Assuntos
Neoplasias Abdominais/terapia , Tumor Desmoplásico de Pequenas Células Redondas/terapia , Neoplasias Abdominais/mortalidade , Neoplasias Abdominais/patologia , Adolescente , Adulto , Terapia Combinada , Procedimentos Cirúrgicos de Citorredução , Tumor Desmoplásico de Pequenas Células Redondas/mortalidade , Tumor Desmoplásico de Pequenas Células Redondas/patologia , Feminino , Humanos , Masculino , Estudos Retrospectivos , Taxa de Sobrevida , Resultado do Tratamento
5.
Cancer Res ; 61(24): 8751-7, 2001 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-11751395

RESUMO

We have demonstrated previously the oncolytic effects of a systemically delivered, replicating vaccinia virus. To enhance the tumor specificity of this vector, we have developed a combined thymidine kinase-deleted (TK-) and vaccinia growth factor-deleted (VGF-) vaccinia virus and investigated its properties in vitro and in vivo. The gene for enhanced green fluorescent protein (EGFP) was inserted into the TK locus of a VGF- vaccinia virus by homologous recombination creating a double-deleted mutant vaccinia virus (vvDD-GFP). Infection of resting and dividing NIH3T3 cells with vvDD-GFP yielded reduced viral recovery compared with wild-type (WT), TK-, or VGF- viruses from resting cultures but equivalent virus recovery from dividing cultures. Eight days after nude mice were injected i.p. with 10(7) plaque-forming units (pfu) of WT, TK-, VGF-, or vvDD-GFP vaccinia virus, tissues and tumor were harvested for viral titer determination. No virus was recovered from the brains of mice injected with vvDD-GFP compared with the other viruses, which ranged from 130 to 28,000 pfu/mg protein; however, equivalent amounts were recovered from tumor. There was no toxicity from vvDD-GFP because nude mice receiving 10(8) pfu of IP vvDD-GFP lived >100 days, whereas mice receiving WT, VGF-, or TK- virus had median survivals of only 6, 17, and 29 days, respectively. Similar results were seen when 10(9) pfu of vvDD-GFP were given. Nude mice bearing s.c. murine colon adenocarcinoma (MC38) had significant tumor regression after treatment with 10(9) pfu of systemic (i.p.) vvDD-GFP compared with control (mean tumor size, 180.71 +/- 35.26 mm(3) versus 2796.79 +/- 573.20 mm(3) 12 days after injection of virus). Our data demonstrate that a TK- and VGF- mutant vaccinia virus is significantly attenuated in resting cells in vitro and demonstrates tumor-specific replication in vivo. It is a promising vector for use in tumor-directed gene therapy, given its enhanced safety profile, tumor selectivity, and the oncolytic effects after systemic delivery.


Assuntos
Deleção de Genes , Terapia Genética/métodos , Peptídeos/genética , Timidina Quinase/genética , Vaccinia virus/genética , Células 3T3 , Animais , Efeito Citopatogênico Viral , Feminino , Vetores Genéticos/genética , Proteínas de Fluorescência Verde , Haplorrinos , Células HeLa , Humanos , Peptídeos e Proteínas de Sinalização Intercelular , Proteínas Luminescentes/biossíntese , Proteínas Luminescentes/genética , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Nus , Infecções por Poxviridae/virologia , Células Tumorais Cultivadas , Vaccinia virus/enzimologia , Vaccinia virus/patogenicidade , Vaccinia virus/fisiologia , Replicação Viral
6.
J Control Release ; 220(Pt A): 210-221, 2015 Dec 28.
Artigo em Inglês | MEDLINE | ID: mdl-26482080

RESUMO

Due to cancer's genetic complexity, significant advances in the treatment of metastatic disease will require sophisticated, multi-pronged therapeutic approaches. Here we demonstrate the utility of a Drosophila melanogaster cell platform for the production and in vivo delivery of multi-gene biotherapeutic systems. We show that cultured Drosophila S2 cell carriers can stably propagate oncolytic viral therapeutics that are highly cytotoxic for mammalian cancer cells without adverse effects on insect cell viability or gene expression. Drosophila cell carriers administered systemically to immunocompetent animals trafficked to tumors to deliver multiple biotherapeutics with little apparent off-target tissue homing or toxicity, resulting in a therapeutic effect. Cells of this Dipteran invertebrate provide a genetically tractable platform supporting the integration of complex, multi-gene biotherapies while avoiding many of the barriers to systemic administration of mammalian cell carriers. These transporters have immense therapeutic potential as they can be modified to express large banks of biotherapeutics with complementary activities that enhance anti-tumor activity.


Assuntos
Drosophila melanogaster/genética , Terapia Genética/métodos , Neoplasias Pulmonares/terapia , Terapia Viral Oncolítica/métodos , Vírus Oncolíticos/genética , Animais , Chlorocebus aethiops , Drosophila melanogaster/citologia , Drosophila melanogaster/imunologia , Drosophila melanogaster/virologia , Feminino , Regulação Neoplásica da Expressão Gênica , Regulação Viral da Expressão Gênica , Células HT29 , Células HeLa , Humanos , Imunocompetência , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/imunologia , Neoplasias Pulmonares/patologia , Neoplasias Pulmonares/virologia , Células MCF-7 , Camundongos Endogâmicos BALB C , Vírus Oncolíticos/imunologia , Vírus Oncolíticos/patogenicidade , Fatores de Tempo , Transfecção , Carga Tumoral , Células Vero , Ensaios Antitumorais Modelo de Xenoenxerto
7.
Surgery ; 130(6): 991-8, 2001 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-11742328

RESUMO

BACKGROUND: Patients with multiple endocrine neoplasia type 1 and hyperparathyroidism often undergo multiple operations because of inadequate initial surgery, presence of supernumerary and ectopic glands, regrowth of remnant glands, or autograft hyperfunction. Management of this patient population is complex. METHODS: From January 1975 to December 2000 we performed 94 reoperative parathyroidectomies consisting of 79 neck reexplorations, 12 autograft removals, and 3 median sternotomies in 75 patients. Data were gathered by retrospective chart review and follow-up telephone interviews. RESULTS: Excluding autograft excision, reoperative surgery was successful (normocalcemia longer than 6 months) in 91%; autograft removal was successful in only 58%. With a median follow-up of 59 months, 64% of patients are currently free from hypercalcemia, and this outcome was not influenced by the total number of glands resected. The median time to recurrent hypercalcemia was 125 months. Thirty patients received an autograft after reoperation. The complication rate for all reoperations was 12%, including permanent recurrent laryngeal nerve injury in 2 patients (2.1%). CONCLUSIONS: Reoperative parathyroidectomy in patients with multiple endocrine neoplasia type 1 was safe and successful in the majority of patients; however, recurrent hyperparathyroidism is likely to develop in most individuals beyond 10 years of follow-up. The total number of glands accounted for after reoperation is not associated with successful outcome.


Assuntos
Hiperparatireoidismo/cirurgia , Neoplasia Endócrina Múltipla Tipo 1/cirurgia , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Monitorização Intraoperatória , Glândulas Paratireoides/transplante , Hormônio Paratireóideo/sangue , Paratireoidectomia , Complicações Pós-Operatórias , Reoperação , Transplante Autólogo
8.
Magn Reson Imaging ; 18(3): 305-9, 2000 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-10745140

RESUMO

The purpose of this study was to evaluate the value of Ferumoxide-enhanced magnetic resonance (MR) imaging in the detection of hepatic metastases in high-risk patients treated for colorectal cancer that have rising CEA. We used 19 patients treated previously for colorectal cancer with rising CEA levels underwent an unenhanced T(1)-weighted (T1W), T(2)-weighted (T2W), STIR, and Ferumoxide-enhanced hepatic MRI. Following these studies, a laparotomy was performed and the liver was evaluated by palpation and intraoperative ultrasound. Two observers who were blinded to surgical results evaluated each MR sequence separately. The number of lesions considered highly suspicious for metastatic lesions were determined for each sequence and were compared to the results of surgery. The McNemar test was used to compare the outcomes of the different sequences. MR Imaging was unable to detect small (<5 mm) metastases discovered at surgery. The best non-contrast sequences for detecting metastases were the STIR with 42% sensitivity, 83% specificity and an overall accuracy of 56% and the T1W sequence (sensitivity 38%, specificity 100%, accuracy 57%), which were not significantly different (p 0.4). The noncontrast T2W sequence had a sensitivity of 29% and a specificity of 77% with an overall accuracy of 46%. When all pre contrast scans were grouped together the common sensitivity was 42%, specificity was 77% and accuracy was 54%. The post-ferumoxide T(2)W scans had a sensitivity of 42%, specificity of 85%, and accuracy of 57%, but did not detect any additional lesions. There was no statistical difference between the pre- and post-contrast studies with regard to identifying patients with metastatic disease (p 0.1). In conclusion, we found small hepatic metastases in patients with early signs of recurrent colorectal cancer are difficult to detect on MRI. Ferumoxide-enhanced MRI was unable to detect additional hepatic metastases and performed no better than unenhanced MRI in detecting small hepatic metastasis.


Assuntos
Antígeno Carcinoembrionário/sangue , Meios de Contraste/administração & dosagem , Ferro , Neoplasias Hepáticas/diagnóstico , Neoplasias Hepáticas/secundário , Recidiva Local de Neoplasia/diagnóstico , Óxidos , Adulto , Idoso , Neoplasias Colorretais/patologia , Dextranos , Feminino , Óxido Ferroso-Férrico , Humanos , Aumento da Imagem , Ferro/administração & dosagem , Neoplasias Hepáticas/sangue , Neoplasias Hepáticas/cirurgia , Imageamento por Ressonância Magnética/métodos , Nanopartículas de Magnetita , Masculino , Pessoa de Meia-Idade , Óxidos/administração & dosagem , Valor Preditivo dos Testes , Reprodutibilidade dos Testes , Sensibilidade e Especificidade
9.
Cancer Gene Ther ; 15(2): 115-25, 2008 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-18084242

RESUMO

In this study, we assessed the ability of a highly tumor-selective oncolytic vaccinia virus armed with a yeast cytosine deaminase gene to infect and lyse human and murine ovarian tumors both in vitro and in vivo. The virus vvDD-CD could infect, replicate in and effectively lyse both human and mouse ovarian cancer cells in vitro. In two different treatment schedules involving either murine MOSEC or human A2780 ovarian carcinomatosis models, regional delivery of vvDD-CD selectively targeted tumor cells and ovarian tissue, effectively delaying the development of either tumor or ascites and leading to significant survival advantages. Oncolytic virotherapy using vvDD-CD in combination with the prodrug 5-fluorocytosine conferred an additional long-term survival advantage upon tumor-bearing immunocompetent mice. These findings demonstrate that a tumor-selective oncolytic vaccinia combined with gene-directed enzyme prodrug therapy is a highly effective strategy for treating advanced ovarian cancers in both syngeneic mouse and human xenograft models. Given the biological safety, tumor selectivity and oncolytic potency of this armed oncolytic virus, this dual therapy merits further investigation as a promising new treatment for metastatic ovarian cancer.


Assuntos
Carcinoma/terapia , Citosina Desaminase/genética , Terapia Viral Oncolítica , Neoplasias Ovarianas/terapia , Saccharomyces cerevisiae/genética , Vaccinia virus/genética , Replicação Viral , Animais , Antimetabólitos/administração & dosagem , Antimetabólitos/uso terapêutico , Carcinoma/tratamento farmacológico , Linhagem Celular Tumoral , Terapia Combinada , Citosina Desaminase/administração & dosagem , Citosina Desaminase/uso terapêutico , Feminino , Flucitosina/administração & dosagem , Flucitosina/uso terapêutico , Humanos , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Nus , Neoplasias Ovarianas/tratamento farmacológico , Saccharomyces cerevisiae/enzimologia , Vaccinia virus/fisiologia , Replicação Viral/genética
10.
Chest Surg Clin N Am ; 5(1): 17-37, 1995 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-7743146

RESUMO

Recent advances in molecular biology have improved our understanding of the pathogenesis of cancer. Molecular genetic alterations have been characterized in lung and esophageal tumors, and have potential clinical application in tumor diagnosis, staging, prevention, and therapy.


Assuntos
Neoplasias Esofágicas/genética , Neoplasias/genética , DNA de Neoplasias/análise , Neoplasias Esofágicas/etiologia , Neoplasias Esofágicas/terapia , Genes Supressores de Tumor/genética , Código Genético , Marcadores Genéticos , Técnicas Genéticas , Terapia Genética , Humanos , Neoplasias/etiologia , Neoplasias/terapia , Oncogenes/genética
11.
J Surg Oncol ; 54(4): 233-8, 1993 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-8255084

RESUMO

The aim of this study was to determine the predictors of long-term survival following surgical resection of thymoma. Forty-one patients with a histologically proven diagnosis of thymoma were evaluated and treated over a 30-year period (1961 to 1991) at our institution. Seven patients (Masaoka stage III or IV) were unresectable and were treated by radiotherapy and/or chemotherapy, with an overall 5 year survival of 50%. Thirty-four patients underwent primary surgical excision of the thymoma, most often through a median sternotomy, with 5- and 10-year survivals of 90%. Complete excision of the thymoma was achieved in 31 patients with a median survival of 54 months vs. 17 months if incomplete. Independent prognostic factors influencing survival were stage, histology, and patients judged to have a benign thymoma at surgery. Although the thymoma was associated with myasthenia gravis (8 patients) and second primary cancers (8 patients), neither factor was associated with overall survival. We conclude that the most significant predictors of long-term survival of thymoma include complete excision, Masaoka stage I disease, and lymphocytic histology. Multivariate analysis suggested that postoperative chemoradiotherapy may impact on survival.


Assuntos
Timoma/mortalidade , Neoplasias do Timo/mortalidade , Adolescente , Adulto , Idoso , Criança , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Estadiamento de Neoplasias , Valor Preditivo dos Testes , Modelos de Riscos Proporcionais , Estudos Retrospectivos , Análise de Sobrevida , Timoma/secundário , Timoma/cirurgia , Timoma/terapia , Neoplasias do Timo/patologia , Neoplasias do Timo/cirurgia , Neoplasias do Timo/terapia
12.
J Virol ; 75(21): 10300-8, 2001 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-11581398

RESUMO

Vaccinia virus is being investigated as a replicating vector for tumor-directed gene therapy. However, the majority of cancer patients have preformed immunologic reactivity against vaccinia virus, as a result of smallpox vaccination, which may limit its use as a vector. The Yaba-like disease (YLD) virus was investigated here as an alternative, replicating poxvirus for cancer gene therapy. We have demonstrated that the YLD virus does not cross-react with vaccinia virus antibodies, and it replicates efficiently in human tumor cells. YLD virus can be expanded and purified to high titer in CV-1 cells under conditions utilized for vaccinia virus. The YLD virus RNA polymerase was able to express genes regulated by a synthetic promoter designed for use in orthopoxviruses. We sequenced the YLD virus TK gene and created a shuttle plasmid, which allowed the recombination of the green fluorescent protein (GFP) gene into the YLD virus. In a murine model of ovarian cancer, up to 38% of cells in the tumor expressed the GFP transgene 12 days after intraperitoneal virus delivery. YLD virus has favorable characteristics as a vector for cancer gene therapy, and this potential should be explored further.


Assuntos
Terapia Genética , Vetores Genéticos , Neoplasias Experimentais/terapia , Poxviridae/genética , Animais , Reações Cruzadas , Feminino , Camundongos , Camundongos Nus , Poxviridae/crescimento & desenvolvimento , Poxviridae/imunologia , Regiões Promotoras Genéticas , Vaccinia virus/genética , Vaccinia virus/crescimento & desenvolvimento , Vaccinia virus/imunologia , Replicação Viral
13.
Gene Ther ; 7(14): 1217-23, 2000 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-10918490

RESUMO

Replicating viruses for cancer gene therapy have beneficial antitumor effects, however, in the setting of an enzyme/prodrug system, the interactions between these viruses and the activated agents are complex. A replicating vaccinia virus expressing the cytosine deaminase gene (VVCD), which converts the prodrug 5-FC into 5-FU, was characterized in vitro and in vivo for its antitumor effects and pathogenicity. Replicating VVCD (+/-5-FC) at various MOIs was used to infect MC38 murine colon adenocarcinoma cells. At high MOIs (>0.1) virus alone was able to kill the majority (65-90%) of cells by day 5 with no additional benefit from prodrug. At low MOIs only the effect of prodrug is seen. Cell lysates demonstrated 300-fold reduced viral recovery from cells treated with both VVCD and 5-FC compared with controls treated with virus alone. Nude mice bearing subcutaneous MC38 tumors were injected with VVCD (or control) and treated with 5FC or control. Mice injected with VVCD (with or without 5FC treatment) had smaller tumors than the controls, suggesting that replicating vaccinia alone is cytotoxic to tumors in vivo. The addition of 5-FC improved the antitumor response when a low dose of virus was injected into tumors. Also, compared with mice that received virus alone, those that received VVCD and 5FC had significantly prolonged survival from virus-mediated death. In conclusion, the addition of an enzyme/prodrug system to a replicating virus can improve the antitumor response and decrease viral pathogenicity. Gene Therapy (2000) 7, 1217-1223.


Assuntos
Adenocarcinoma/terapia , Neoplasias do Colo/terapia , Flucitosina/uso terapêutico , Nucleosídeo Desaminases/genética , Pró-Fármacos/uso terapêutico , Vaccinia virus/efeitos dos fármacos , Animais , Citosina Desaminase , Relação Dose-Resposta a Droga , Interações Medicamentosas , Flucitosina/metabolismo , Fluoruracila/metabolismo , Fluoruracila/uso terapêutico , Terapia Genética/métodos , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Nus , Pró-Fármacos/metabolismo , Células Tumorais Cultivadas , Vaccinia virus/enzimologia , Vaccinia virus/genética , Replicação Viral/efeitos dos fármacos
14.
Int J Cancer ; 72(5): 739-45, 1997 Sep 04.
Artigo em Inglês | MEDLINE | ID: mdl-9311587

RESUMO

As part of our ongoing studies to characterize molecular alterations in a well-defined series of surgically resected esophageal cancers, we examined the expression of 2 ras-regulated genes, whose products (osteopontin and cathepsin L) previously were shown to be associated with tumor invasion and metastasis. RNA was extracted from primary esophageal tumors (adenocarcinomas, 19; squamous-cell carcinomas, 6) and matched histologically normal esophageal mucosa from the distant resection margin. Northern analysis was used to quantitate RNA, relative to an 18S rRNA control, and immunohistochemistry to assess the tissue distribution of osteopontin. In addition, H-, K- and N-ras mutations were studied in the same tissues using PCR and hybridization with allele (mutant)-specific oligonucleotide probes. We demonstrated a K-ras mutation (codon 12, GTT) in one esophageal adenocarcinoma. The ras-regulated gene osteopontin was over-expressed in 100% of squamous-cell carcinomas and in 58% of adenocarcinomas relative to matched normal esophageal mucosa. Patterns of immunoreactivity for osteopontin protein also varied between squamous-cell carcinomas (tumor cell staining) and adenocarcinomas (predominantly tumor-infiltrating macrophages). Expression of cathepsin L also varied with esophageal tumor histology, with over-expression in 58% of primary esophageal adenocarcinomas and 33% of squamous-cell cancers.


Assuntos
Adenocarcinoma/genética , Carcinoma de Células Escamosas/genética , Catepsinas/genética , Endopeptidases , Neoplasias Esofágicas/genética , Genes ras/genética , Mutação , Sialoglicoproteínas/genética , Adenocarcinoma/química , Sequência de Bases , Carcinoma de Células Escamosas/química , Catepsina L , Cisteína Endopeptidases , Neoplasias Esofágicas/química , Feminino , Genes p53/genética , Humanos , Imuno-Histoquímica , Masculino , Osteopontina , Reação em Cadeia da Polimerase , Polimorfismo Conformacional de Fita Simples , RNA Mensageiro/metabolismo , Análise de Sequência , Sialoglicoproteínas/análise , Proteína Supressora de Tumor p53/análise
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA